CandidatesPreclinicalPhase 1Phase 2Phase 3reg. filingmarketedpartner
FOTIVDA
VEGFR TKI

TIVO-3 US (RCC following two+ prior systemic therapies)

TIVO-1 Ex-US (RCC 1st line)*

eusa-logo

TiNivo-2 (+/- OPDIVO® in RCC following prior CPI)**

bms-logo

DEDUCTIVE (+ IMFINZI® in HCC)***

az-logo

RCC (+ NKT2152)****

nkt-logo
Ficlatuzumab
Anti-HGF/c-MET
IgG1 mAb

HNSCC (+/- ERBITUX® in refractory disease)

Pancreatic (+ Nab-paclitaxel + gemcitabine)

CyFi-1 (+HiDac in AML)

AV-380
Anti-GDF15 IgG1 mAb

Cachexia/Oncology

AV-203
Anti-ERBB3 IgG1 mAb

Oncology

AV-353
Anti-Notch 3 IgG1 mAb

Oncology

FOTIVDA
ProgressPreclinPhase 1Phase 2Phase 3Reg. FilingMarketed

TIVO-3 US (RCC following two+ prior systemic therapies)

TIVO-1 Ex-US (RCC 1st line)*

TiNivo-2 (+/- OPDIVO® in RCC following prior CPI)**

DEDUCTIVE (+ IMFINZI® in HCC)***

RCC (+ NKT2152)****

Ficlatuzumab
ProgressPreclinPhase 1Phase 2Phase 3Reg. FilingMarketed

HNSCC (+/- ERBITUX® in refractory disease)

Pancreatic (+ Nab-paclitaxel + gemcitabine)

CyFi-1 (+HiDac in AML)

AV-380
ProgressPreclinPhase 1Phase 2Phase 3Reg. FilingMarketed

Cachexia/Oncology

AV-203
ProgressPreclinPhase 1Phase 2Phase 3Reg. FilingMarketed

Oncology

AV-353
ProgressPreclinPhase 1Phase 2Phase 3Reg. FilingMarketed

Oncology

*Partnered with EUSA Pharma (Europe)
**Partnered with Bristol Myers Squibb
***Partnered with AstraZeneca
****Partnered with NKT

AVEO Oncology is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the United States. FOTIVDA is AVEO’s first commercial product and was approved by the U.S. Food and Drug Administration (FDA) for marketing and sale in the United States on March 10, 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop tivozanib in immuno-oncology combinations in RCC and other indications, and AVEO has other investigational programs in clinical development.

Based on FOTIVDA’s demonstrated anti-tumor activity, tolerability profile and reduction of regulatory T-cell production, AVEO and its collaboration partners are continuing to develop tivozanib in RCC and in additional cancer indications with significant unmet medical needs including, hepatocellular carcinoma, and tumors that are resistant to immunotherapy, or immunologically cold tumors, in combination with immune checkpoint inhibitors. In addition, AVEO is evaluating tivozanib as a monotherapy and cholangiocarcinoma. AVEO and AVEO’s collaboration partners or independent investigators sponsor the development of tivozanib through preclinical studies and clinical trials conducted under collaboration agreements and investigator sponsored trial agreements or AVEO’s Cooperative Research and Development Agreement with the National Cancer Institute’s Surgical Oncology Program.

AVEO is also seeking to advance its pipeline of four wholly owned immunoglobulin G1 monoclonal antibody product candidates, ficlatuzumab, AV-380, AV-203 and AV-353. AVEO aims to leverage its existing collaborations and partnerships and enter into new strategic collaborations and partnerships to continue to advance each of its product candidates.

Focused on Patients. Driven by Science.